POLISCOPE
Back to feed
NewsReutersMay 5, 2026United States

White House Estimates $529 Billion Savings from New Drug Pricing Deals

The White House Council of Economic Advisers projects that new agreements with 17 pharmaceutical companies to align U.S. drug prices with international rates could save the economy $529 billion over the next decade. While the administration touts these deals as a major cost-reduction measure, Democratic lawmakers and outside analysts have raised questions regarding the transparency of the agreements and the actual impact on consumer costs.

healthcareprescription drugseconomymedicaidfederal budget
Read the full story at Reuters

Why It Matters

This policy aims to lower prescription drug costs for U.S. consumers and government programs like Medicaid by tying domestic prices to international benchmarks, potentially impacting drug affordability and pharmaceutical industry revenue over the next ten years.

Key Facts

  • The White House estimates a $529 billion economy-wide savings over 10 years from the 'most favored nation' drug pricing policy.
  • Federal and state governments are projected to save $64.3 billion on Medicaid over the next decade.
  • The administration has reached agreements with 17 leading pharmaceutical companies.
  • The White House has not released the full text of the agreements, citing sensitive data that could impact financial markets.
  • Total U.S. spending on prescription drugs reached $467 billion in 2024.
  • The Congressional Budget Office previously estimated a similar plan could reduce drug prices by more than 5%.
  • A report from Sen. Bernie Sanders' staff found that 15 companies participating in the plan saw combined profits increase by 66% to $177 billion over the past year.
  • Senate Democrats, led by Ron Wyden, have introduced a measure to require public disclosure of the terms of these pharmaceutical agreements.

Who's Mentioned

otherBernie SanderspersonRon Wyden“Senate Finance Committee Ranking Member, D-Ore.”organizationCongressional Budget Office“Provided independent analysis of similar drug pricing policies”personBernie Sanders“U.S. Senator, I-Vt.”personRobert F. Kennedy Jr.“Health Secretary”otherDonald TrumporganizationDepartment of Health and Human Services“Federal department overseeing the drug-pricing deals”otherWhite HouseotherHealth Secretary Robert F. Kennedy Jr.personDonald Trump“President of the United States”organizationWhite House Council of Economic Advisers“Conducted the economic analysis of the drug pricing policy”otherRon Wyden